{"id":"https://openalex.org/G268317455","display_name":"A novel Stratified Medicine Algorithm to predict treatment responses to host-directed therapy in TB patients.","description":"Tuberculosis (TB) is a chronic, life-threatening infectious disease which poses a tremendous challenge for physicians, researchers and Health Systems, which treatment is long, based only on the drug susceptibility of the responsible infective strain and very costly in drug-resistant cases (MDR-TB). The European Region still has the highest prevalence of MDR-TB in the world. Host-Directed Therapies (HDT) have been recently proposed to shorten treatment length and by to improve the patients\u2019 outcomes while not increasing the risk of generating drug resistance.\nAs hyperinflammation is responsible of the lung damage associated to patients\u2019 worse outcomes and sequelae, one of the approaches is to add an HDT with anti-inflammatory effect to the current drug regimen to cure the patients faster while having less permanent lung damage. Because TB has a wide range of clinical forms and severity stages, any therapeutic regimen needs to be studied in clinical trials (CT) as its benefit might differ among patients. No individualized personalized medicine is possible without stratifying the patients by integrating pathogen and host factors that will predict the course of the disease and the response to the intervention.\nSMA-TB objectives are:\n\u2022\tTo evaluate in a CT the potential impact of acetylsalicylic acid (ASA) and Ibuprofen (Ibu) (anti-inflammatoriesy HDT) as adjuncts to standard therapy for drug sensitive (DS-) and MDR-TB. This potentially will reduce tissue damage, decrease the length of the treatment and the risk of bad outcomes.\n\u2022\tTo identify and clinically validate host and pathogen biomarkers for further selection according to their relevance in terms of their ability to predict TB course and outcomes and response to treatment thanks to data science protocol.\n\u2022\tTo generate a medical algorithm to stratify patients using network-based mathematical modelling for predicting the course of the disease and its response to the intervention, to be applied during clinical management to improve and personalize TB.","funder_award_id":"847762","funder":{"id":"https://openalex.org/F4320320300","display_name":"European Commission","doi":"10.13039/501100000780"},"funded_outputs":["https://openalex.org/W3128527002","https://openalex.org/W3155640403","https://openalex.org/W3182947028","https://openalex.org/W3203344925","https://openalex.org/W4286890065","https://openalex.org/W4310675773","https://openalex.org/W4311462823","https://openalex.org/W4376612939","https://openalex.org/W4377022924","https://openalex.org/W4382196729","https://openalex.org/W4386083811","https://openalex.org/W4391777496","https://openalex.org/W4393093610","https://openalex.org/W4410477721","https://openalex.org/W4410827577","https://openalex.org/W4410845265","https://openalex.org/W4410893310","https://openalex.org/W4417151699","https://openalex.org/W4417415711","https://openalex.org/W6912079412","https://openalex.org/W6930787020","https://openalex.org/W6931483225","https://openalex.org/W6949178580","https://openalex.org/W6949276970","https://openalex.org/W6949766986","https://openalex.org/W6950593009","https://openalex.org/W6967233415","https://openalex.org/W6968020036","https://openalex.org/W6968303104","https://openalex.org/W6968895385","https://openalex.org/W6969209815","https://openalex.org/W6969232059","https://openalex.org/W7135213285","https://openalex.org/W7166835223","https://openalex.org/W7214642146","https://openalex.org/W7221441397"],"funded_outputs_count":36,"parent_awards":[],"sub_awards":[],"sub_awards_count":0,"amount":6388104.0,"currency":"EUR","amount_usd":7176396.03,"amount_usd_basis":"daily_rate","recipients":[{"id":null,"display_name":"ACADEMISCH ZIEKENHUIS LEIDEN","ror":null,"country_code":"NL","roles":["partner"],"share":null,"basis":"funder_reported","asserted_by":"funder"},{"id":null,"display_name":"ANAXOMICS BIOTECH SL","ror":null,"country_code":"ES","roles":["partner"],"share":null,"basis":"funder_reported","asserted_by":"funder"},{"id":null,"display_name":"LIONEX GMBH","ror":null,"country_code":"DE","roles":["partner"],"share":null,"basis":"funder_reported","asserted_by":"funder"},{"id":null,"display_name":"NATIONAL CENTER FOR LUNG HEALTH JSC","ror":null,"country_code":"GE","roles":["partner"],"share":null,"basis":"funder_reported","asserted_by":"funder"},{"id":null,"display_name":"OSLO UNIVERSITETSSYKEHUS HF","ror":null,"country_code":"NO","roles":["partner"],"share":null,"basis":"funder_reported","asserted_by":"funder"},{"id":null,"display_name":"TES2A EUROPE CONSULTING AND BUSINESS DEVELOPMENT SL","ror":null,"country_code":"ES","roles":["partner"],"share":null,"basis":"funder_reported","asserted_by":"funder"},{"id":null,"display_name":"WITS HEALTH CONSORTIUM (PTY) LTD","ror":null,"country_code":"ZA","roles":["partner"],"share":null,"basis":"funder_reported","asserted_by":"funder"},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","roles":["partner"],"share":null,"basis":"affiliation_matcher","asserted_by":"funder"},{"id":"https://openalex.org/I4210137002","display_name":"Institut d'Investigaci\u00f3 en Ci\u00e8ncies de la Salut Germans Trias i Pujol","ror":"https://ror.org/03bzdww12","country_code":"ES","roles":["lead"],"share":null,"basis":"affiliation_matcher","asserted_by":"funder"}],"recipient_countries":[{"country_code":"ES","share":0.3831,"amount_usd":2749277.32,"basis":"organisation_location"},{"country_code":"ZA","share":0.1733,"amount_usd":1243669.43,"basis":"organisation_location"},{"country_code":"NO","share":0.1315,"amount_usd":943696.08,"basis":"organisation_location"},{"country_code":"FR","share":0.1028,"amount_usd":737733.51,"basis":"organisation_location"},{"country_code":"NL","share":0.0959,"amount_usd":688216.38,"basis":"organisation_location"},{"country_code":"GE","share":0.0938,"amount_usd":673145.95,"basis":"organisation_location"},{"country_code":"DE","share":0.0196,"amount_usd":140657.36,"basis":"organisation_location"}],"recipient_regions":[],"research_scope":{"is_research":true,"basis":"funder_default","tier":1},"funding_type":"research","funder_scheme":"H2020 - RIA","start_date":"2020-01-01","end_date":"2024-12-31","start_year":2020,"end_year":2024,"landing_page_url":"https://cordis.europa.eu/project/id/847762","doi":"10.3030/847762","provenance":"cordis","lead_investigator":{"given_name":null,"family_name":null,"orcid":null,"role_start":null,"affiliation":{"name":"INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL","country":"ES","ids":null}},"co_lead_investigator":null,"investigators":null,"works_api_url":"https://api.openalex.org/works?filter=awards.id:G268317455","primary_topic":null,"topics":null,"institution_awarded":[{"id":"https://openalex.org/I4210137002","display_name":"Institut d'Investigaci\u00f3 en Ci\u00e8ncies de la Salut Germans Trias i Pujol","ror":"https://ror.org/03bzdww12","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210137002","https://openalex.org/I4387153040"]}],"updated_date":"2026-10-17T03:01:12.000Z","created_date":"2026-07-13T04:29:53.000Z"}